Correlation between In Vitro Activity of Posaconazole and In Vivo Efficacy against Rhizopus oryzae Infection in Mice
Authors:
- 1 May 2010
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (5) , 1665-1669
Abstract
We have evaluated the in vitro activity of posaconazole (PSC) against 50 clinical strains of Rhizopus oryzae using a broth microdilution method, the Neo-Sensitabs tablet diffusion method, and minimal fungicidal concentration (MFC) determination. In general, PSC showed low MICs against this fungus, and the MICs correlated with the inhibition zone diameters. Most of the MFCs, however, were from 1 to 4 dilutions higher than their corresponding MICs. We then investigated the efficacies of several different doses of PSC in a murine model. All treatments began 24 h after challenge and lasted for 7 days. The drug was administered twice a day to mice infected with three strains that showed intermediate PSC susceptibility (MIC = 2 μg/ml) and three PSC-susceptible strains (MIC = 0.25 μg/ml). A dose of 10 mg/kg of body weight was ineffective, while doses of 20 and 30 mg/kg prolonged the survival of the mice. The 50 strains tested were segregated into two groups on the basis of the in vitro data. For the group with the most strains (85%), the strains had low PSC MICs, mice infected with the strains showed higher rates of survival (30 to 40%), and PSC was able to reduce the fungal load in the kidney and less regularly in the brain. For the second group (15% of the strains), the strains had intermediate PSC MICs, mice infected with the strains had lower survival rates (10 to 20%), and PSC treatment resulted in variable and no reductions in the fungal loads in the kidneys and brains, respectively.Keywords
This publication has 21 references indexed in Scilit:
- Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated InfectionAntimicrobial Agents and Chemotherapy, 2009
- Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal InfectionAntimicrobial Agents and Chemotherapy, 2007
- Posaconazole Prophylaxis in Experimental Systemic ZygomycosisAntimicrobial Agents and Chemotherapy, 2007
- Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 CasesClinical Infectious Diseases, 2006
- Posaconazole as Salvage Therapy for ZygomycosisAntimicrobial Agents and Chemotherapy, 2006
- Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosisDiagnostic Microbiology and Infectious Disease, 2004
- Activity of Posaconazole in Treatment of Experimental Disseminated ZygomycosisAntimicrobial Agents and Chemotherapy, 2003
- Optimal Testing Conditions for Determining MICs and Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Uncommon Molds: NCCLS Collaborative StudyJournal of Clinical Microbiology, 2002
- Antifungal Susceptibility Testing: Practical Aspects and Current ChallengesClinical Microbiology Reviews, 2001
- Do In Vitro Susceptibility Data Predict the Microbiologic Response to Amphotericin B? Results of a Prospective Study of Patients withCandidaFungemiaThe Journal of Infectious Diseases, 1998